Seeking AlphaCodex · 实盘不做把握 4/10
北京时间·🕒 发布 12:48:20(美东 00:48)·⟳ 抓取 12:53:58 +5m38s·⚡ 决策 07-24 12:54:49 +51s·95.2 天前
Scribe Therapeutics 上调规模并按区间高端完成 IPO 定价
IPO 以区间高端 15 美元定价且规模上调，说明一级市场需求尚可。
📄 原文Seeking Alpha↗ 原文
Scribe Therapeutics prices upsized IPO at $15/share
Scribe Therapeutics (SCTX) priced its upsized IPO of 8.58M shares at $15.00 per share, the top of its marketed range. I…
不做 Scribe Therapeutics（SCTX.US）
新股尚未开始交易且无真实二级市场报价，IPO 定价高端只能说明发行需求，无法给出可回测的同向入场边界，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-24 · 扩散 medium · price-in 风险 medium ↗
关键理由
- IPO 以区间高端 15 美元定价且规模上调，说明一级市场需求尚可。
- 但 SCTX 是今日才开始交易的新股，缺少上市后真实价格、流动性和盘口承接，无法形成可回测的正期望入场。
- 正文中的 CRSP 是 CRISPR 技术语境，不构成对 CRISPR Therapeutics 的明确公司级催化。
主要风险
- 新股首日开盘价可能大幅偏离发行价，盘前无法判断是否已透支定价。
- 临床阶段基因编辑公司尚无商业化收入支撑，首日波动主要由新股供需决定。
原文全文
展开原文 · 778 字
Scribe Therapeutics (SCTX) priced its upsized IPO of 8.58M shares at $15.00 per share, the top of its marketed range.
It is a clinical-stage biotechnology company engineering purpose-built in vivoCRISPR technologies (CRSP)designed to extend healthy lifespan through disease prevention and durable therapeutic intervention.
Gross proceeds are expected to be about $128.7M and shares are expected to begin trading on the Nasdaq under the ticker SCTX.
The offering is expected to close on July 27, 2026.
The underwriters have a 30-day option to purchase up to an additional 1.28M shares to cover over-allotments.
The proceeds will be used to advance Scribe's gene-editing pipeline, including its lead cardiometabolic program, and for working capital and general corporate purposes.
It is a clinical-stage biotechnology company engineering purpose-built in vivoCRISPR technologies (CRSP)designed to extend healthy lifespan through disease prevention and durable therapeutic intervention.
Gross proceeds are expected to be about $128.7M and shares are expected to begin trading on the Nasdaq under the ticker SCTX.
The offering is expected to close on July 27, 2026.
The underwriters have a 30-day option to purchase up to an additional 1.28M shares to cover over-allotments.
The proceeds will be used to advance Scribe's gene-editing pipeline, including its lead cardiometabolic program, and for working capital and general corporate purposes.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。